RSS

PamGene

Article Date:  Mar 03 2009


Together with scientific partners, its Scientific Advisory Board and commercial partners such as Johnson & Johnson and Merck & Co, PamGene has developed an outstanding platform for high-throughput micro-array-based multi-parameter testing. The current focal point is the discovery and patenting of oncology biomarkers through the unique Matching Medicines platform. PamGene’s Matching Medicines approach ultimately aims to provide medical oncologists with valuable additional data to create the best plan for a particular patient. This helps guide the selection of likely responders and prevents non-responders having to needlessly undergo treatment with a specific drug, thereby avoiding unnecessary side effects as well as lost time.

This story is from Growth Company Investor, the independent voice on fast-growing companies. Subscribe today for the latest AIM recommendations.

Comments 

There are currently no comments on this article

Sign up and get...

  • Regular GrowthBusiness newsletters
  • Post comments on articles
Sign up

Research

  • Directors' Pay AIM 2009

    What should an AIM company pay its CEO or FD?
    What should a non-executive director or chairman expect to be paid?
    What benchmarks should AIM remuneration committee members be using when
    setting pay?

VCT Special Report 2009

This reports principle aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest.

Cash Shells Special Report 2009

A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape.

More

Events Calendar

The Media Magnate Awards 2009

26th March, Vinopolis, London

More

More News: Small-Cap Spotlight

Cape Lambert in £85m project sale

Aussie-based Cape Lambert Resources is selling its Lady Annie copper mine for A$135 million to Hong Kong-quoted China Sci-Tech.

Diamondcorp persists with funding

Gem miner Diamondcorp is hoping the strong recovery in rough diamond prices will facilitate its planned £5 million funding.

Cheap money dulls Brady

Lower returns on cash balances have flattened commodity trading software specialist Brady's annual pre-tax profits to £1 million.

Advertisement

Related articles

Speakers

InteRNA Technologies (NL)

Galapagos (BEL)

Galapagos

Poll

Which currency will gain most this year?





Have your vote on current issues

People who read this also read

  • Sumus keeps up expansion

    Profiled here at 45p early last year, shares in Sumus moved as high as 55p but have since settled back at 45.5p.

  • Contact

     

  • Contact

  • Warthog's snout in £2.1m trough

    Games software developer Warthog unveiled a £2.1 million fundraising with institutions today to finance deals and boost working capital, writes James Crux.

  • Gem find puts European Diamonds on a high

    After a diamond was found in a sample from Lentiira in Finland, European Diamonds' chief executive Roy Spencer said today at the company's AGM that 'there is a significant chance that we will find a kimberlite of economic size within a year'. Ben Cobley reports.

White Papers

12 Key Points to Consider When Selecting a Network Scanning Solution

Discover the 12 key points your company should consider before you evaluate and select a vulnerability assessment solution.

1Z0-040 Oracle Database 10G New Features for Administrators Practice Exam

Oracle 9i administrators can certify on Oracle 10G by passing this exam. The ExamForce 1Z0-040 Oracle Database 10G New Features for Administrators practice exam provides their unique triple testing mode to instantly set a baseline of your knowledge and focus your study where you need it most.

2009 Employment Screening Practices Benchmarking Report

A Valuable Tool to Help You Assess the Strength and Potential of Your Screening Program.

More